Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Operating Income Loss of -$145.82 million for the year ending 2025.
- BridgeBio Oncology Therapeutics, Inc. showed a decrease of -80.3% in Operating Income Loss from 2024 to 2025.
- This data is from BridgeBio Oncology Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 3 years of available data (2023 to 2025), BridgeBio Oncology Therapeutics, Inc.'s Operating Income Loss has declined by 349,653.0%.
- Historical annual values: Fiscal year 2025: -$145.82 million | Fiscal year 2024: -$80.86 million | Fiscal year 2023: -$41.7 thousand.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: